Monte Rosa Therapeutics Inc (NASDAQ:GLUE) has a beta value of 1.30 and has seen 4.56 million shares traded in the last trading session. The company, currently valued at $568.07M, closed the last trade at $8.84 per share which meant it lost -$0.06 on the day or -0.67% during that session. The GLUE stock price is -40.27% off its 52-week high price of $12.40 and 67.08% above the 52-week low of $2.91. If we look at the company’s 10-day average daily trading volume, we find that it stood at 10.54 million shares traded. The 3-month trading volume is 1.95 million shares.
The consensus among analysts is that Monte Rosa Therapeutics Inc (GLUE) is Buy stock at the moment, with a recommendation rating of 1.00. 0 analysts rate the stock as a Sell, while 0 rate it as Overweight. 1 out of 5 have rated it as a Hold, with 4 advising it as a Buy. 0 have rated the stock as Underweight. The expected earnings per share for the stock is -0.49.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Monte Rosa Therapeutics Inc (NASDAQ:GLUE) trade information
Sporting -0.67% in the red in last session, the stock has traded in the red over the last five days, with the highest price hit on recent trading when the GLUE stock price touched $8.84 or saw a rise of 8.68%. Year-to-date, Monte Rosa Therapeutics Inc shares have moved 56.46%, while the 5-day performance has seen it change -6.75%. Over the past 30 days, the shares of Monte Rosa Therapeutics Inc (NASDAQ:GLUE) have changed 73.67%. Short interest in the company has seen 5.23 million shares shorted with days to cover at 8.36.
Monte Rosa Therapeutics Inc (GLUE) estimates and forecasts
Figures show that Monte Rosa Therapeutics Inc shares have outperformed across the wider relevant industry. The company’s shares have gained 53.47% over the past 6 months, with this year growth rate of 30.42%, compared to 17.50% for the industry.
7 analysts offering their estimates for the company have set an average revenue estimate of 2.62M for the current quarter. 6 have an estimated revenue figure of 2.82M for the next ending quarter.
If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was -96.71% over the past 5 years.
GLUE Dividends
Monte Rosa Therapeutics Inc is expected to release its next earnings report in December this year, and investors are excited at the prospect of better dividends despite the company’s debt issue.
Monte Rosa Therapeutics Inc (NASDAQ:GLUE)’s Major holders
Insiders own 0.71% of the company shares, while shares held by institutions stand at 84.24% with a share float percentage of 84.84%. Investors are also buoyed by the number of investors in a company, with Monte Rosa Therapeutics Inc having a total of 116.0 institutions that hold shares in the company. The top two institutional holders are NEA MANAGEMENT COMPANY, LLC with over 7.69 million shares worth more than $28.77 million. As of 2024-06-30, NEA MANAGEMENT COMPANY, LLC held 12.7872% of shares outstanding.
The other major institutional holder is PRICE T ROWE ASSOCIATES INC /MD/, with the holding of over 5.98 million shares as of 2024-06-30. The firm’s total holdings are worth over $22.36 million and represent 9.9368% of shares outstanding.
